Leadership Overview
Intas has 10 executives leading key functions including strategy, operations, finance, marketing, information technology, legal, emerging markets, animal health, sales, and quality.
Driven by a commitment to innovation, Intas is dedicated to advancing global healthcare through the research and manufacturing of high-quality pharmaceuticals, impacting lives worldwide.
Driven by a commitment to innovation, Intas is dedicated to advancing global healthcare through the research and manufacturing of high-quality pharmaceuticals, impacting lives worldwide.
Leadership Roles at Intas
Nimish Chudgar - Chief Executive Officer
Nimish Chudgar, the Chief Executive Officer at Intas, directs the company's overall strategic vision and operational execution. This leadership role involves guiding Intas's global expansion and ensuring alignment with its core mission of pharmaceutical research and manufacturing. Chudgar oversees the integration of all business units, driving efficiency and fostering innovation across the organization. The Chief Executive Officer's responsibilities include setting financial targets, managing stakeholder relations, and championing the company's commitment to quality and accessibility in healthcare. By focusing on sustainable growth and market leadership, Nimish Chudgar ensures Intas maintains its competitive edge in the global pharmaceutical landscape. This executive's strategic direction is paramount to the company's continued success and its ability to deliver life-changing medicines.
Abhimanyu Ojha - Global Chief Financial Officer & Global President, Finance
Abhimanyu Ojha, the Global Chief Financial Officer & Global President, Finance at Intas, directs all financial strategies and fiscal operations for the global enterprise. This executive is responsible for financial planning, budgeting, capital allocation, and ensuring the financial health and stability of Intas. Ojha oversees accounting, treasury, and investor relations, providing critical financial insights to support strategic decision-making. The Global Chief Financial Officer & Global President, Finance plays a key role in managing financial risks, optimizing profitability, and driving revenue growth through sound financial management. By ensuring robust financial controls and transparent reporting, Abhimanyu Ojha supports Intas's mission to expand its pharmaceutical research and manufacturing capabilities. This leadership ensures the company's financial integrity and supports its long-term growth objectives.
Kirti Maheshwari - Chief Operating Officer
Kirti Maheshwari, the Chief Operating Officer at Intas, manages the day-to-day operational activities critical to the company's pharmaceutical manufacturing and research endeavors. This executive ensures the seamless execution of production schedules, supply chain logistics, and operational efficiency across all Intas facilities. Maheshwari's oversight extends to optimizing resource allocation and implementing best practices in manufacturing processes to uphold the highest standards of quality and compliance. The Chief Operating Officer plays a vital part in scaling operations to meet growing global demand for Intas's pharmaceutical products. By driving operational excellence, Kirti Maheshwari directly contributes to the company's ability to deliver affordable and effective medicines to markets worldwide. This leadership ensures the robust functioning of the company's core business.
C. Yagnik - President, Legal
C. Yagnik, the President, Legal at Intas, directs all legal affairs and ensures regulatory compliance across the company's global operations. This executive provides strategic legal counsel on matters related to pharmaceutical manufacturing, research, intellectual property, and corporate governance. Yagnik oversees the legal team, managing litigation, contracts, and ensuring adherence to international and local legal frameworks governing the pharmaceutical industry. The President, Legal is critical in mitigating legal risks and safeguarding Intas's corporate interests. By maintaining a strong legal foundation, C. Yagnik supports Intas's mission to provide high-quality pharmaceuticals while operating with integrity and within all applicable laws and regulations. This leadership ensures the company's ethical and lawful conduct.
Giridhar Venugopal - President, Emerging Markets & Bd
Giridhar Venugopal, the President, Emerging Markets & Bd at Intas, drives the company's strategic initiatives and business development within key emerging markets globally. This executive focuses on expanding Intas's presence and market share in these regions, tailoring product offerings and market strategies to local needs. Venugopal oversees the establishment and growth of distribution networks, partnerships, and sales operations in these critical territories. The President, Emerging Markets & Bd is instrumental in navigating the unique regulatory and commercial landscapes of emerging economies. By fostering strong relationships and implementing effective market entry strategies, Giridhar Venugopal significantly contributes to Intas's global growth trajectory and its mission to make essential medicines accessible worldwide.
Vijay Teng - Global President, Animal Health & Fertility
Vijay Teng, the Global President, Animal Health & Fertility at Intas, leads the strategic direction and commercial operations for the company's animal health and fertility product portfolios. This executive is responsible for driving growth, innovation, and market penetration for these specialized therapeutic areas across global markets. Teng oversees product development, marketing, sales, and distribution strategies tailored to the animal health and fertility sectors. The Global President, Animal Health & Fertility plays a vital role in expanding Intas's reach and impact within these important segments of the pharmaceutical industry. By focusing on specialized needs and advancing veterinary and reproductive health solutions, Vijay Teng contributes to Intas's diversified product offerings and its commitment to improving health outcomes.
Venugopal Vijayendran - President, Marketing & Sales (India)
Venugopal Vijayendran, the President, Marketing & Sales (India) at Intas, directs all marketing and sales initiatives within the Indian domestic market. This executive is responsible for developing and executing strategies to enhance brand visibility, drive product adoption, and achieve sales targets across India. Vijayendran oversees the sales force, manages marketing campaigns, and ensures effective distribution of Intas's pharmaceutical products throughout the country. The President, Marketing & Sales (India) plays a crucial role in strengthening Intas's position as a leading pharmaceutical provider in its home market. By fostering strong customer relationships and understanding local market dynamics, Venugopal Vijayendran significantly contributes to the company's revenue generation and market leadership in India.
Avinash Joshi - President, Quality
Avinash Joshi, the President, Quality at Intas, oversees the comprehensive quality assurance and quality control systems across all pharmaceutical manufacturing and research operations. This executive ensures that all products meet stringent global regulatory standards and Intas's internal quality benchmarks. Joshi leads initiatives to maintain and enhance product integrity, safety, and efficacy, driving a culture of quality throughout the organization. The President, Quality is paramount in upholding Intas's reputation for excellence and compliance in the highly regulated pharmaceutical industry. By ensuring adherence to Good Manufacturing Practices (GMP) and other critical quality guidelines, Avinash Joshi safeguards patient well-being and supports the company's commitment to delivering reliable and effective medicines worldwide.
Anshu Verma - Senior General Manager, External Manufacturing (Chief Marketing Officer and CDMO)
Anshu Verma, the Senior General Manager, External Manufacturing (Chief Marketing Officer and CDMO) at Intas, spearheads the company's external manufacturing partnerships and contract development and manufacturing organization (CDMO) services. This executive manages relationships with external manufacturing partners, ensuring adherence to Intas's stringent quality and production standards. Verma oversees the strategic growth of the CDMO business, attracting new clients and expanding service offerings in pharmaceutical development and manufacturing. The Senior General Manager, External Manufacturing (Chief Marketing Officer and CDMO) is instrumental in leveraging Intas's manufacturing expertise to serve a broader market. By optimizing external production capabilities, Anshu Verma enhances Intas's market reach and revenue streams, contributing significantly to the company's overall business strategy and operational capacity.
Shivam Mittal - Executive Vice President & Global Chief Information Officer
Shivam Mittal, the Executive Vice President & Global Chief Information Officer at Intas, leads the company's global information technology strategy and infrastructure. This executive is responsible for developing and implementing robust IT systems that support Intas's pharmaceutical research, manufacturing, and business operations. Mittal oversees cybersecurity, data management, digital transformation initiatives, and ensures the technological backbone of Intas is secure, efficient, and scalable. The Executive Vice President & Global Chief Information Officer plays a crucial role in enhancing operational productivity and fostering innovation through advanced technology solutions. By driving digital advancements, Shivam Mittal ensures Intas remains at the forefront of technological integration in the pharmaceutical industry, supporting global market access and operational excellence.
Explore Leadership Teams in Manufacturing
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
Bausch Health Companies Inc. operates as a global pharmaceutical and healthcare products company focused on developing, manufacturing, and marketing a broad portfolio of branded pharmaceuticals, generic medicines, over-the-counter healthcare products, and medical devices. The organization works to improve patient health outcomes by delivering therapeutic solutions across multiple medical specialties. Through its research, development, and commercial operations, the company serves healthcare providers, hospitals, pharmacies, and patients across numerous international markets. The company functions as a diversified healthcare enterprise with business segments that address several therapeutic and medical device categories. Its core focus areas include gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and ophthalmology. By maintaining a broad therapeutic portfolio, the organization supports healthcare professionals in diagnosing, managing, and treating a wide range of medical conditions that affect millions of patients globally.
Company Leadership
TU
JS
Tolmar Pharmaceuticals is a fully integrated pharmaceutical company focused on the innovative development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Urology. Tolmar global headquarters, product development and manufacturing facilities are based in Northern Colorado, while North America commercial headquarters is based in Buffalo Grove, Illinois.
Company Leadership AD
JL
AC
Hemofarm is the leading pharmaceutical company in Serbia and in the region. Care for your health is the company's most important commitment. Hemofarm is a leader in the Serbian pharmaceutical market with a 17.3% share in financial terms. Holding a 79.1% share in the export of Serbian pharmaceutical products, the Vrac-based company is at the same time the leading Serbian exporter of medicinal products. Hemofarm produces over 4 billion tablets and capsules a year.
Company Leadership DS
DV
VA
TM
Frequently Asked Questions Regarding Intas Top Executives and Leadership Team
